ONC206: Dose 1
Phase 2Small molecule
Jazz PharmaceuticalsONC206: Dose 1 is one of 32 small molecule programs targeting Paraganglioma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
31
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
31 competitors in Paraganglioma
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbApproved
Taxol
TevaApproved
Keppra
UCBApproved
Erivedge
RocheApproved
Vimpat
UCBApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Camptosar
PfizerApproved
Afinitor
NovartisApproved
Kisqali
NovartisApproved
Velban
Eli LillyApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ONC206: Dose 1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company